Developer docs
API playgroundTry for free, no card

Search company profiles

Bold Capital Partners

Full company profile

uuid00042zb

Namestring
Bold Capital Partners
Legal namestring
BOLD Capital Partners
Company typeenum
Private
Founded yearint
2015
Descriptiontext

Bold Capital Partners is a privately held, early-stage venture capital firm founded in 2015 and headquartered in Santa Monica, California, with a second office in Boston. The firm invests across two thematic pillars — Health & Life Sciences (longevity, patient-enabled health management, synthetic biology) and Deep Tech & Productivity (AI, blockchain, sensors, VR, 3D printing, robotics) — anchored by a "convergence" thesis targeting the intersection of physical, digital, virtual, and biological technologies. The portfolio spans more than 50 companies, including current holdings such as Colossal Biosciences, Centivax, Near Space Labs, ProRata.ai, Hosta AI, and Gallant Pet, alongside realized exits including Insilico Medicine (SEHK IPO), Deep Longevity (SEHK IPO), CareSignal, Mighty Buildings, IVIVA Medical, and Docbot.

The firm monetizes through the standard VC model of management fees on assets under management and carried interest on realized portfolio exits. It sources and originates deals through direct founder outreach, partner networks, and industry conference participation, and distributes capital via direct equity investments, often participating in syndicates and occasionally leading rounds (e.g., the $25 million seed for The Biological Computing Company in 2026). Marketing and deal-flow generation is supported by an active LinkedIn and Twitter presence, a published News & Ideas content hub, and the affiliated BOLD Longevity Growth (BLG.VC) sub-brand, which extends the platform into dedicated longevity investing.

The team is led by co-founder Peter Diamandis alongside managing partner Teymour Boutros-Ghali, CFO William Meeker, and principal Will Borthwick. The firm is founder/partner-led with no disclosed parent or institutional LP backing in the input data, and there is no public listing or ticker. No information on AUM, fee structure, or fund size is publicly disclosed, which limits visibility into revenue mechanics despite an evident high deal cadence across 2025-2026.

Short descriptiontext

Bold Capital Partners is a privately held, early-stage venture capital firm investing in transformative companies across health and life sciences and deep tech, with a portfolio spanning AI, biotech, aerospace, and synthetic biology. Founded in 2015 and headquartered in Santa Monica, it serves bold founders building convergence technologies.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersSanta Monica, United States
HQ citystring
Santa Monica
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
venture capital funding, early-stage investing, life sciences investment, deep tech venture, frontier technology investing
Industry3 codes
PRIMARYFSANAAAB
Early-Stage Venture Capital (Series A/B)
SECONDARYFSANAJAN
SDG / Thematic Sustainable Investment Funds
Financial & Insurance/Private Equity & Venture Capital/Impact / ESG & Sustainable Investment Funds
SECONDARYBPADACAO
Impact Investment & Development Investment Funds
Business & Public Services/International Organizations & Development/International Financial Institutions & Development Banks
NAICS code2 codes
  • Securities, Commodity Contracts, and Other Financial Investments and Related Activities523
  • Other Investment Pools and Funds5259
SIC code2 codes
  • Investment Advice6282
  • Investors, Nec6799
Product category
Venture Capital
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model2 records
1Management Fees
TypeSubscription Recurring
Description

Standard VC management fees typically charged as a percentage of assets under management

boldcapitalpartners.com
2Carried Interest
TypeTransaction Fee
Description

Performance-based carried interest from successful portfolio company exits and realizations

boldcapitalpartners.com
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Operations, Technology or R&D, Marketing or Sales, Others
GTM typeB2B
B2B
Offering typeServices
Services
Brand1 record
1BOLD Longevity Growth
Description

A longevity-focused investment initiative within BOLD Capital Partners

boldcapitalpartners.com
Core offering1 text field

Bold Capital Partners is an early-stage venture capital firm that invests capital into founders and companies developing transformative technologies. The firm deploys funds across two main verticals: Health & Life Sciences (longevity, synthetic biology, patient-enabled health) and Deep Tech & Productivity (AI, blockchain, sensors, VR, 3D printing, robotics). Bold Capital also operates BOLD Longevity Growth (BLG.VC) as an affiliated fund vehicle focused on longevity investing.

Differentiator
Functional benefit
Problem solved
Product overview1 text field

Bold Capital Partners is a venture capital firm that invests in people and technologies transforming the world. The firm focuses on two primary areas: Health & Life Sciences (including longevity, patient-enabled health management, synthetic biology) and Deep Tech & Productivity (including AI, blockchain, sensors, VR, 3D printing, robotics). The firm deploys capital into early-stage companies and manages investment portfolios across these transformative technology sectors.

Product and service2 records
1Venture Capital Investment Management
CategoryVenture Capital
Description

Early-stage venture capital investment services providing capital, strategic guidance, and network access to founders and companies developing transformative technologies. Focuses on Health & Life Sciences (longevity, synthetic biology, patient-enabled health) and Deep Tech & Productivity (AI, blockchain, sensors, VR, 3D printing, robotics).

2BOLD Longevity Growth (BLG.VC)
CategoryVenture Capital
Description

Affiliated longevity-focused investment fund vehicle operating under the Bold Capital Partners umbrella, extending the firm's investment reach into longevity and aging-related technologies. Located at the same Santa Monica address.

Scale indicator2 records

Each record includes

Type, Value, Description, Source

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Early-stage VC investing in frontier science and technology, including deep tech, biotech, AI, and aerospace. Strong overlap with Bold's convergence-of-exponential-tech thesis and target founder profile.

TypeOthers
Description

Private investment bank and investor with selective venture exposure across transformative technology. Adjacent to Bold as a fellow independent, founder-led investor with selective frontier exposure.

TypeDirect peer
Description

Early-stage venture firm that seeds founders building category-defining companies. Comparable to Bold in stage focus (seed/Series A) and commitment to transformational technology founders.

TypeDirect peer
Description

Early-to-growth stage venture firm backing transformative technologies in biotech, aerospace, AI, and frontier tech. Comparable to Bold in willingness to invest in contrarian, science-heavy categories.

TypeDirect peer
Description

Deep-tech venture firm backing founders applying frontier science — including AI, biology, materials, and aerospace — to transform large industries. Directly comparable to Bold's deep-tech mandate.

TypeDirect peer
Description

Specialist early-stage investor in life sciences, biotech, and physical sciences. Highly comparable to Bold's health and life sciences vertical and willingness to lead deep-science rounds.

TypeDirect peer
Description

Early-stage VC investing at the intersection of technology, science, and global impact. Comparable to Bold in horizontal, frontier-tech orientation and willingness to back deep-tech and biotech founders.

TypeDirect peer
Description

Early-stage venture firm investing across frontier technology, healthcare, and biotech with a willingness to back bold, science-driven bets. Closely comparable to Bold Capital in thesis (transformative tech, life sciences) and stage (seed to growth).

TypeDirect peer
Description

Venture firm investing in transformative companies across health, energy, and frontier tech with a thematic 'world positive' lens. Comparable to Bold's mission-driven framing of transformative technology.

TypeBroad incumbent
Description

Large multi-stage venture firm with dedicated bio/health and frontier-tech franchises. Comparable to Bold in scope (AI, biotech, deep tech) but operates at significantly larger fund scale and brand recognition.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers1 record

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment1 record

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature1 record

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles4 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds1 record

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors1 record

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment136 records

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Bold Capital Partners

Bold Capital Partners is a privately held, early-stage venture capital firm investing in transformative companies across health and life sciences and deep tech, with a portfolio spanning AI, biotech, aerospace, and synthetic biology. Founded in 2015 and headquartered in Santa Monica, it serves bold founders building convergence technologies.

What Bold Capital Partners does

Bold Capital Partners is a privately held, early-stage venture capital firm founded in 2015 and headquartered in Santa Monica, California, with a second office in Boston. The firm invests across two thematic pillars — Health & Life Sciences (longevity, patient-enabled health management, synthetic biology) and Deep Tech & Productivity (AI, blockchain, sensors, VR, 3D printing, robotics) — anchored by a "convergence" thesis targeting the intersection of physical, digital, virtual, and biological technologies. The portfolio spans more than 50 companies, including current holdings such as Colossal Biosciences, Centivax, Near Space Labs, ProRata.ai, Hosta AI, and Gallant Pet, alongside realized exits including Insilico Medicine (SEHK IPO), Deep Longevity (SEHK IPO), CareSignal, Mighty Buildings, IVIVA Medical, and Docbot.

The firm monetizes through the standard VC model of management fees on assets under management and carried interest on realized portfolio exits. It sources and originates deals through direct founder outreach, partner networks, and industry conference participation, and distributes capital via direct equity investments, often participating in syndicates and occasionally leading rounds (e.g., the $25 million seed for The Biological Computing Company in 2026). Marketing and deal-flow generation is supported by an active LinkedIn and Twitter presence, a published News & Ideas content hub, and the affiliated BOLD Longevity Growth (BLG.VC) sub-brand, which extends the platform into dedicated longevity investing.

The team is led by co-founder Peter Diamandis alongside managing partner Teymour Boutros-Ghali, CFO William Meeker, and principal Will Borthwick. The firm is founder/partner-led with no disclosed parent or institutional LP backing in the input data, and there is no public listing or ticker. No information on AUM, fee structure, or fund size is publicly disclosed, which limits visibility into revenue mechanics despite an evident high deal cadence across 2025-2026.

Bold Capital Partners firmographics

Firmographics
Name
Bold Capital Partners
Legal name
BOLD Capital Partners
Website
https://boldcapitalpartners.com
Company type
Private
Founded year
2015
Operating status
Operating
Headcount range
11–50 employees
Short description
Bold Capital Partners is a privately held, early-stage venture capital firm investing in transformative companies across health and life sciences and deep tech, with a portfolio spanning AI, biotech, aerospace, and synthetic biology. Founded in 2015 and headquartered in Santa Monica, it serves bold founders building convergence technologies.
Ownership category
akta.pro rank

Bold Capital Partners industry classification

Industry
Product category
Venture Capital
NAICS
Securities, Commodity Contracts, and Other Financial Investments and Related Activities (523), Other Investment Pools and Funds (5259)
SIC
Investment Advice (6282), Investors, Nec (6799)
akta.pro industry
PRIMARYFSANAAAB
Early-Stage Venture Capital (Series A/B)
SECONDARYFSANAJAN
SDG / Thematic Sustainable Investment Funds
Financial & Insurance/Private Equity & Venture Capital/Impact / ESG & Sustainable Investment Funds
SECONDARYBPADACAO
Impact Investment & Development Investment Funds
Business & Public Services/International Organizations & Development/International Financial Institutions & Development Banks

Keywords

  • Venture capital funding
  • Early-stage investing
  • Life sciences investment
  • Deep tech venture
  • Frontier technology investing

Where Bold Capital Partners is headquartered

Location

Headquarters

HQ city
Santa Monica
HQ country
United States
HQ region
North America

Offices2 records

Markets served

Bold Capital Partners business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Operations, Technology or R&D, Marketing or Sales, Others

Revenue model

  1. Management Fees: Standard VC management fees typically charged as a percentage of assets under management
  2. Carried Interest: Performance-based carried interest from successful portfolio company exits and realizations

Go-to-market motion1 record

Distribution channels1 record

Marketing channels4 records

Bold Capital Partners product offering

Product offering

Core offering

Bold Capital Partners is an early-stage venture capital firm that invests capital into founders and companies developing transformative technologies. The firm deploys funds across two main verticals: Health & Life Sciences (longevity, synthetic biology, patient-enabled health) and Deep Tech & Productivity (AI, blockchain, sensors, VR, 3D printing, robotics). Bold Capital also operates BOLD Longevity Growth (BLG.VC) as an affiliated fund vehicle focused on longevity investing.

Product overview

Bold Capital Partners is a venture capital firm that invests in people and technologies transforming the world. The firm focuses on two primary areas: Health & Life Sciences (including longevity, patient-enabled health management, synthetic biology) and Deep Tech & Productivity (including AI, blockchain, sensors, VR, 3D printing, robotics). The firm deploys capital into early-stage companies and manages investment portfolios across these transformative technology sectors.

Differentiator

Problem solved

Functional benefit

Brands

  • BOLD Longevity Growth: A longevity-focused investment initiative within BOLD Capital Partners

Products and services

  • Venture Capital Investment Management Early-stage venture capital investment services providing capital, strategic guidance, and network access to founders and companies developing transformative technologies. Focuses on Health & Life Sciences (longevity, synthetic biology, patient-enabled health) and Deep Tech & Productivity (AI, blockchain, sensors, VR, 3D printing, robotics).
  • BOLD Longevity Growth (BLG.VC) Affiliated longevity-focused investment fund vehicle operating under the Bold Capital Partners umbrella, extending the firm's investment reach into longevity and aging-related technologies. Located at the same Santa Monica address.

Companies that use Bold Capital Partners

Customer profile

Named customers1 record

Segments1 record

Ideal customer profiles1 record

Bold Capital Partners technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature1 record

Bold Capital Partners partnerships and signals

Strategic signal

Scale indicators2 records

Recent moves6 records

Expansion highlights5 records

Bold Capital Partners competitors and assessment

Company assessment

Direct peers

  • Lux Capital: Early-stage VC investing in frontier science and technology, including deep tech, biotech, AI, and aerospace. Strong overlap with Bold's convergence-of-exponential-tech thesis and target founder profile.
  • First Round Capital: Early-stage venture firm that seeds founders building category-defining companies. Comparable to Bold in stage focus (seed/Series A) and commitment to transformational technology founders.
  • Founders Fund: Early-to-growth stage venture firm backing transformative technologies in biotech, aerospace, AI, and frontier tech. Comparable to Bold in willingness to invest in contrarian, science-heavy categories.
  • DCVC (Data Collective): Deep-tech venture firm backing founders applying frontier science — including AI, biology, materials, and aerospace — to transform large industries. Directly comparable to Bold's deep-tech mandate.
  • ARCH Venture Partners: Specialist early-stage investor in life sciences, biotech, and physical sciences. Highly comparable to Bold's health and life sciences vertical and willingness to lead deep-science rounds.
  • Innovation Endeavors: Early-stage VC investing at the intersection of technology, science, and global impact. Comparable to Bold in horizontal, frontier-tech orientation and willingness to back deep-tech and biotech founders.
  • Khosla Ventures: Early-stage venture firm investing across frontier technology, healthcare, and biotech with a willingness to back bold, science-driven bets. Closely comparable to Bold Capital in thesis (transformative tech, life sciences) and stage (seed to growth).
  • Obvious Ventures: Venture firm investing in transformative companies across health, energy, and frontier tech with a thematic 'world positive' lens. Comparable to Bold's mission-driven framing of transformative technology.

Others

  • Allen & Company: Private investment bank and investor with selective venture exposure across transformative technology. Adjacent to Bold as a fellow independent, founder-led investor with selective frontier exposure.

Broad incumbents

  • Andreessen Horowitz (a16z): Large multi-stage venture firm with dedicated bio/health and frontier-tech franchises. Comparable to Bold in scope (AI, biotech, deep tech) but operates at significantly larger fund scale and brand recognition.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks5 records

Key highlights6 records

Customer concentration

Bold Capital Partners social profiles

Digital presence

Bold Capital Partners financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Bold Capital Partners leadership team

Management profile

Number of profiles

Profiles4 records

Bold Capital Partners funding detail

Funding detail

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Bold Capital Partners M&A and investment

M&A and investment

M&A

Investments136 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Bold Capital Partners

What does Bold Capital Partners do?

Bold Capital Partners is an early-stage venture capital firm that invests capital into founders and companies developing transformative technologies. The firm deploys funds across two main verticals: Health & Life Sciences (longevity, synthetic biology, patient-enabled health) and Deep Tech & Productivity (AI, blockchain, sensors, VR, 3D printing, robotics). Bold Capital also operates BOLD Longevity Growth (BLG.VC) as an affiliated fund vehicle focused on longevity investing.

Is Bold Capital Partners a public or private company?

Bold Capital Partners is a private company. It is classified as founder individual operated bootstrapped and is currently operating.

When was Bold Capital Partners founded?

Bold Capital Partners was founded in 2015. It employs 11 to 50 people.

Where is Bold Capital Partners based?

Bold Capital Partners is headquartered in Santa Monica, United States, in the North America region.

How does Bold Capital Partners make money?

Two revenue lines are on record. Management Fees are the primary driver. The others are carried Interest.

Who are Bold Capital Partners's main competitors?

Direct peers on record are Lux Capital, First Round Capital, Founders Fund, DCVC (Data Collective), ARCH Venture Partners, Innovation Endeavors, Khosla Ventures and Obvious Ventures. Allen & Company is listed as an others. Andreessen Horowitz (a16z) is listed as a broad incumbent.

Does Bold Capital Partners have an API?

No public API is recorded for Bold Capital Partners.

What industry is Bold Capital Partners in?

Bold Capital Partners's product category is Venture Capital. Its primary akta.pro industry code is FSANAAAB, Early-Stage Venture Capital (Series A/B), with a secondary code of FSANAJAN, SDG / Thematic Sustainable Investment Funds. Its NAICS code is 523 and its SIC code is 6282.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
EntarabiMagicCube Secures Strategic Investment From e& in $10 Million Post-Quantum Security RoundMagicCube closed the second tranche of its $10 million funding round with a strategic investment from e& Capital. The company provides software-based security for payments, identity, and digital assets. The investment supports its platform as a hardware-independent trust layer for secure digital infrastructure.Mobile World Livee& pumps cash into sovereign security start-upe& invested $10 million in MagicCube, a software company developing sovereign-grade post-quantum security for AI, identity, and payments. The investment, made through e& capital group, joins Verifone and existing investors. MagicCube aims to deliver hardware-free security for critical workloads across regions and cloud providers.FinSMEsMagicCube Receives Investment from e& capitalMagicCube, a payments and identity security firm, raised $10M in a funding round led by e& capital, joining Verifone, Bold Capital Partners, and Mosaik Partners. The company's SDT platform secures payments, digital IDs, and AI services across devices, serving banks, telcos, and enterprises.Pulse 2.0KeyCare: $27.4 Million Raised For Epic-Based Virtual Care Platform Scaling AI-Enabled Primary And Urgent CareKeyCare, a virtual care company built natively on Epic, has raised $27.4 million in a new financing round led by HealthX Ventures with participation from 8VC, LRVHealth, BOLD Capital Partners, Ikigai Venture Partners, and strategic investors including WellSpan Health, Allina Health, University of Chicago Ventures, Edge Ventures, and Exact Sciences Inc., bringing its total capital raised to more than $55 million. The company will use the funds to deepen AI-enabled technology investment, expand operational capacity to meet rising demand from health system partners, and scale its platform offering integrated 24/7 virtual urgent, preventive, and primary care services. KeyCare positions itself as a primary care extension partner for health systems, with all patient visits remaining connected to the patient's home health system for care coordination.FinSMEsEvergreen Select Raises Additional $6M in FundingEvergreen Select, a cultivated meat company, raised an additional $6M in funding led by S2G Investments, BOLD Capital Partners, and Good Startup. The round brings total funding to over $55M, which the company will use to expand operations and development. The company aims to provide scalable cultivated beef to the beef industry.YahooAqtual Raises Over $30M as It Scales Novel cfDNA PlatformAqtual raised $31 million in Series B funding, with Bold Capital and Bold Longevity Growth joining previous investors. The capital supports its cfDNA platform and the PRIMA-102 trial in rheumatoid arthritis, which has enrolled over 1,300 patients and is expected to complete in Q4 2025.Business Wire BlogAqtual Raises Over $30M as It Scales Novel cfDNA PlatformAqtual raised $31 million in Series B funding from Bold Capital, Bold Longevity Growth, and previous investors. The capital will advance its cfDNA platform and commercialization of a rheumatoid arthritis test, with a clinical trial expected to complete in Q4 2025.PR NewswireCentivax Raises Oversubscribed $45 Million Series A Led by Future Ventures to Advance Universal Flu Vaccine into Clinic and Expand Universal Immunity PortfolioCentivax closed an oversubscribed $45 million Series A led by Future Ventures, with participation from NFX, BOLD Capital, and others. The funding will advance its universal flu vaccine to Phase I clinical trials within eight months. The company also expanded its universal immunity portfolio beyond flu.BloombergSamsung Is Said in Talks to Invest in California-Based ExoSamsung Ventures is among firms seeking to invest in Exo Imaging in a private fundraising round led by Sands Capital, Bold Capital, and Qubit Health Capital. The company could raise about $100 million total.PR NewswireDiscure Technologies Announces $16 Million in Financing Led by BOLD Capital Partners, Supernova Invest and Sanara CapitalDiscure Technologies Ltd. has secured $16 million in total financing, which includes $11 million from an oversubscribed Series A round and a $5 million SAFE raise, aimed at advancing its innovative device for treating degenerative disc disease. The funding was led by BOLD Capital Partners, Supernova Invest, and Sanara Capital, reflecting strong investor confidence in Discure's approach to addressing the underlying causes of the disease. This investment will support the company in conducting its First-in-Human clinical study in Canada and Italy, marking a significant step towards effective treatment solutions for patients suffering from degenerative disc disease.